Abstract:Gastrointestinal first‐pass metabolism plays an important role in bioavailability and in drug–drug interactions. Physiologically‐based pharmacokinetic (PBPK) modeling is a powerful tool to integrate these processes mechanistically. However, a correct bottom‐up prediction of GI first‐pass metabolism is challenging and depends on various model parameters like the level of enzyme expression and the basolateral intestinal mucosa permeability (Pmucosa). This work aimed to investigate if cytochrome P450 (CYP) 3A4 expression could help predict the first‐pass effect using PBPK modeling or whether additional factors like Pmucosa do play additional roles using PBPK modeling. To this end, a systematic review of the absolute CYP3A expression in the human gastrointestinal tract and liver was conducted. The resulting CYP3A4 expression profile and two previously published profiles were applied to PBPK models of seven CYP3A4 substrates (alfentanil, alprazolam, felodipine, midazolam, sildenafil, triazolam, and verapamil) built‐in PK‐Sim®. For each compound, it was assessed whether first‐pass metabolism could be adequately predicted based on the integrated CYP3A4 expression profile alone or whether an optimization of Pmucosa was required. Evaluation criteria were the precision of the predicted interstudy bioavailabilities and area under the concentration–time curves. It was found that none of the expression profiles provided upfront an adequate description of the extent of GI metabolism and that optimization of Pmucosa as a compound‐specific parameter improved the prediction of most models. Our findings indicate that a pure bottom‐up prediction of gastrointestinal first‐pass metabolism is currently not possible and that compound‐specific features like Pmucosa must be considered as well.

Research advances in models of hepatic and intestinal first-pass drug metabolism

Analyzing the metabolic fate of oral administration drugs: A review and state-of-the-art roadmap.

Absorption Barriers in the Rat Intestinal Mucosa: 2. Application of Physiologically Based Mathematical Models to Quantify Mechanisms of Drug Permeation and Metabolism

Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination

Advantages,disadvantages and applications of in vitro hepatic metabolic models

An update on the potential role of intestinal first-pass metabolism for the prediction of drug–drug interactions: the role of PBPK modeling

Advances in Intestinal Transporters for the Absorption of Drugs

Advances in models for predicting drug intestinal permeability

Microfluidic models in liver drug metabolism research

Study on the Effect Factors of Bioavailability Using in Vitro Models

[Advances and Related Issues in the Use of in Vitro Methods to Predict Metabolic Clearance Rate of New Drugs].

Extrahepatic Metabolism of Drug

Hepatic Metabolism: A Key Component of Herbal Drugs Research

Intestinal Absorption And First-Pass Metabolism Of Polyphenol Compounds In Rat And Their Transport Dynamics In Caco-2 Cells

Recent Advances On In Silico Adme Modeling

Developments in Methods for Measuring the Intestinal Absorption of Nanoparticle-Bound Drugs

Mechanistic Study of Absorption and First-Pass Metabolism of GL-V9, a Derivative of Wogonin

Quantitative prediction of pharmacokinetic properties of drugs in humans: Recent advance in in vitro models to predict the impact of efflux transporters in the small intestine and blood-brain barrier

PBPK modeling: What is the role of CYP3A4 expression in the gastrointestinal tract to accurately predict first‐pass metabolism?

Homology Study Between Human Drug Metabolizing Enzymes and Intestinal Microbial Metabolizing Enzymes

An update on oral drug delivery via intestinal lymphatic transport